KOD — Kodiak Sciences Share News
0.000.00%
Last trade - 00:00US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
Kodiak Sciences rises after eye-disease drugs meet late-stage trial goals
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake
U.S. STOCKS ON THE MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia
Kodiak Sciences rises after eye-disease drugs meet trial goals
Brief: Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile
Kodiak Sciences Inc. reports results for the quarter ended June 30 - Earnings Summary
Kodiak Sciences Q2 net loss widens on higher R&D costs
Brief: Kodiak Sciences Q2 Net Income USD -65.643 Million
Brief: Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Kodiak Sciences Q1 net loss narrows as R&D rises
Brief: Kodiak Sciences Q1 Net Income USD -58.158 Million
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Kodiak Sciences Q4 net loss widens on higher R&D spending
Brief: Kodiak Sciences Q4 Net Income USD -56.736 Million